Education
About Us
Working with TipRanks
Follow Us
Disc Medicine (IRON)
NASDAQ:IRON
IRON Stock Chart & Stats
Day’s Range― - ―
52-Week Range$25.64 - $68.73
Previous CloseN/A
Volume41.94K
Average Volume (3M)343.07K
Market Cap
$1.72B
Enterprise Value$1.43B
Total Cash (Recent Filing)$1.21M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.74
Next Earnings
May 19, 2025EPS Estimate
-1.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.99
Shares Outstanding34,569,042
10 Day Avg. Volume368,089
30 Day Avg. Volume343,066
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-16.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-14.34K
Enterprise Value/Ebitda-13.24
Forecast
1Y Price Target
$98.50Price Target Upside98.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
---
Disc Medicine News
PremiumCompany Announcements
Disc Medicine’s 2024 Financial Results and Clinical Progress---
Bulls Say, Bears Say
Bulls Say
Financial PositionThe company's current cash position of $489.9M is expected to fund its operational plans into 2028, providing strong financial backing for future development.
Market ExpansionThe company's engagement with the EMA for potential EU approval indicates a strategic move to capture both US and EU markets.
Regulatory ApprovalBitopertin is on the path for accelerated approval after a successful meeting with the FDA, which aligns with the design for the post-marketing confirmatory Phase 3 study.
Bears Say
Clinical DevelopmentDISC-0974 and DISC-3405 represent intriguing upside drivers where key data is awaited.
Market PerceptionThere is a belief that the market has not fully appreciated the value and potential of DISC-0974 in addressing anemia in myelofibrosis, which could be benchmarked against a pricing of approximately $200,000.
Regulatory ChallengesThe potential for accelerated approval for bitopertin represents the key area of focus for IRON.
---
Ownership Overview
26.62% Insiders
13.42% Mutual Funds
33.60% Other Institutional Investors
18.33% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IRON FAQ
What was Disc Medicine’s price range in the past 12 months?
Disc Medicine lowest stock price was $25.64 and its highest was $68.73 in the past 12 months.
What is Disc Medicine’s market cap?
Disc Medicine’s market cap is $1.72B.
When is Disc Medicine’s upcoming earnings report date?
Disc Medicine’s upcoming earnings report date is May 19, 2025 which is in 47 days.
How were Disc Medicine’s earnings last quarter?
Disc Medicine released its earnings results on Feb 27, 2025. The company reported -$0.95 earnings per share for the quarter, beating the consensus estimate of -$1.096 by $0.146.
Is Disc Medicine overvalued?
According to Wall Street analysts Disc Medicine’s price is currently Undervalued.
Does Disc Medicine pay dividends?
Disc Medicine does not currently pay dividends.
What is Disc Medicine’s EPS estimate?
Disc Medicine’s EPS estimate is -1.14.
How many shares outstanding does Disc Medicine have?
Disc Medicine has 34,569,042 shares outstanding.
What happened to Disc Medicine’s price movement after its last earnings report?
Disc Medicine reported an EPS of -$0.95 in its last earnings report, beating expectations of -$1.096. Following the earnings report the stock price went up 0.073%.
Which hedge fund is a major shareholder of Disc Medicine?
Currently, no hedge funds are holding shares in IRON
---
Disc Medicine Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$98.50 (98.43% Upside)
$98.50 (98.43% Upside)
Blogger Sentiment
Bullish
IRON Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 713.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $41.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-20.26%
12-Months-Change
Fundamentals
Return on Equity
-27.73%
Trailing 12-Months
Asset Growth
34.99%
Trailing 12-Months
Company Description
Disc Medicine
Disc Medicine (IRON) is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for the treatment of hematologic diseases. The company's core products are designed to address conditions related to iron homeostasis, such as anemia and iron overload disorders. Disc Medicine aims to innovate within the hematology sector by developing drugs that can provide effective solutions for patients with unmet medical needs.
---
IRON Stock 12 Month Forecast
Average Price Target
$98.50
▲(98.43% Upside)
Technical Analysis
Best Analysts Covering IRON
1 Year
1 Year Success Rate
10/16 ratings generated profit
1 Year Average Return
+4.18%
reiterated a buy rating last month
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +4.18% per trade.
---